UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus ...

Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus ...

(RTTNews) - UCB (UCB) and Biogen Inc. (BIIB) presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate.

UCB and Biogen’s lupus drug has met its primary endpoint in a Phase III trial, but the companies are yet to release the study data. The PHOENYCS GO study (NCT04294667) evaluated dapirolizumab ...

UCB is listed on Euronext Brussels (symbol: UCB). Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s ...

Biogen Inc.’s stock was slightly lower Tuesday, shedding early gains made after the company and Belgian partner UCB announced positive results in a late-stage trial of a treatment for the ...

You can reach Adam on Signal at stataf.54. Biogen and UCB said Tuesday that an experimental drug reduced disease activity and symptoms of systemic lupus, achieving the primary goal of a placebo ...

Sept 24 (Reuters) - Biogen (BIIB.O), opens new tab and Belgian partner UCB (UCB.BR), opens new tab said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in ...

Biogen and UCB’s gamble on advancing into phase 3 on the back of a failed study looks to have paid off, with the partners reporting positive top-line results in systemic lupus erythematosus (SLE ...